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Abstract
Parasitic infections (e.g.,  malaria and helminthiases) have a huge impact on public
health  in  endemic  areas.  Moreover,  parasitic  infestations  are  prominent  causes  of
anemia in the tropics and subtropics, further perpetuated by malnutrition, inflamma‐
tory, and genetic diseases. Anemia-associating parasitic infections vary depending on
the requirements and pathophysiology of the parasites. There is an interplay between
different factors that can be segregated as host and parasite factors, resulting in severe
anemia  accompanying  these  parasitic  infestations.  The  pathophysiological  mecha‐
nisms leading to anemia associated with the different parasites vary greatly, includ‐
ing hemolysis, anemia of inflammation, bone marrow suppression, and micronutrients
deficiency. The major means to deal with this anemia include prevention and treat‐
ment of such infestations.
Keywords: malaria, schistosomiasis, anemia, pathogenesis, parasite
1. Overview
Parasitic infestations (e.g., malaria and helminthiases) have an enormous impact on public
health in endemic areas. Moreover, parasitic infections are leading causes of anemia in the
tropics  and  subtropics,  worsened  by  malnutrition,  inflammatory,  and  genetic  diseases.
Anemia-associating parasitic infections vary depending on the requirements and pathophysi‐
ology of the parasites. It sounds reasonable that the closer the parasite's association with the
red blood cells  (RBCs),  the more severe the expected anemia.  On speaking about blood
parasites, malaria is the most important and well-known infection worldwide. Anemia is a
clinical condition where the values of hemoglobin, hematocrit, or RBCs counts are more than
two standard deviations below the mean for a particular age and sex, with severe anemia
characterized by hemoglobin of less than 5 g/dL. Anemia develops as a consequence of blood
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loss, when red cells are destructed prematurely, or when the normal erythroid production of
red cells is disturbed. These mechanisms often overlap with a number of factors contribu‐
ting to anemia.  Among the important causes of increased cell  destruction leading to ac‐
quired hemolytic anemia is malaria. Hypersplenism and splenomegaly as in hyper-reactive
malaria also play an important role in hemolysis. Another blood parasite of importance is
schistosomiasis which is caused by a blood fluke that undergoes a complex life cycle using a
species of freshwater snail. Adult flukes pair post maturation inside a human host, for life and
begets thousands of eggs that brings harm to organs and are excreted in urine and feces. The
larvae hatching from the eggs manage their way into the snails that in turn begets vast numbers
of larvae capable of penetrating the human skin. The fluke lives in the veins, urinary blad‐
der, and large intestine of their human hosts and borrow molecules from their hosts to put on
their surfaces so that the hosts’ immune system would not recognize them as strange.
2. Malaria and anemia
Malaria is an ancient febrile illness that continues to jeopardize human existence. It is one of
the major killers, particularly among the tropical countries in Africa, Southeast Asia, and Latin
America which is a mosquito-borne disease the characteristic symptoms of which are cyclical
bouts of fever with muscle stiffness, shivering, and sweating whose periodicity reflects the
intraerythrocytic cycle. Malaria is a disease resulting from the parasitic infestation by
Plasmodium species, such as Plasmodium falciparum, P. malariae, P. ovale, P. vivax, and P. knowlesi
with P. falciparum being the most virulent. Malaria is estimated to be a burden for over 200
million people, leading to more than one million fatalities annually. The main vector for this
Plasmodium is Anopheline species, which are most common tropical inhabitants [1]. Malaria is
dependent on the vector-human cycle, and it affects impoverished people in the suburban‐
ized endemic areas with economic and social consequences. Despite decades of efforts on the
battle against malaria, it remains to be an important health threat in tropical areas [2]. Malaria
can manifest a vast clinical spectrum from silent carrier to fatal shock.
3. Common clinical features of malaria
Fever
Chills
Headache
Myalgia
Malaise
Anemia
Petechie
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4. Manifestations of severe disease
Seizures
Jaundice
Mental confusion
Renal failure
Acute respiratory disease syndrome (ARDS)
Coma
Thrombocytopenia
Severe anemia
Hypoglycemia
Hyperparasitemia
Hypotension
Bleeding
Blackwater fever
5. Genetic basis of malaria-associated anemia
Malaria is a polygenic disease, and the genetic basis of malaria-related anemia is under study.
Variable genes have been shown to be involved in host predisposition to the severe forms of
malaria, part of which is malaria-related anemia; nevertheless, it is likely that there are
undetected malaria-susceptibility genes. It has been found that severe malaria-related anemia
is associated with a number of genes, such as FcγRIIA-131H/FcγRIIIB-NA2 haplotype,
interleukin-13 promoter polymorphisms (-7402 T/G and -4729G/A), and TNF-238 A allele [3–
5]. The host-parasite interaction is complex and not fully understood. Such an interaction leads
to a release of a number of cytokines, resulting in the so-called "cytokine storm" in the setting
of severe malaria, where injurious cytokines and small molecules become dysregulated and
results in a systemic inflammatory response syndrome (SIRS)-like state characterized by high
circulating levels of tumor necrosis factor (TNF) and nitric oxide. However, evidence of direct
correlation between severe malaria and the activity of these markers is limited [6]. Elevated
serum levels of the different cytokines such as TNF, lymphotoxin, interleukins 6, 10, 12, and
18, and macrophage inflammatory protein (MIP)-1 are seen in the setting of malaria.
Nevertheless, more studies are needed to clarify whether these predate or follow clinical
markers of severe infection [6]. It is proposed that interferon-regulated gene transcripts
influence the inflammatory response to cytokines, and these results demonstrated previous‐
ly undiscovered transcriptional changes in the host that might govern the development of
malaria-associated syndromes, such as anemia and metabolic dysregulation [7]. On the other
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hand, a number of genes were found to be protecting against malarial anemia such as SCGF,
also called C-type lectin domain family member 11A [CLEC11A]), IL12Bpro-2/3’ UTR-T
haplotype, FcγRIIA-131H/FcγRIIIB-NA1 haplotype, and NOS2 promoter polymorphisms,
along with HLA class II allele DQB1*0501 [3, 8, 9]. In addition, specific genes for commonly
inherited diseases found in the tropics are also known for their role in resistance to malaria-
related anemia. Such effects imposed by these genes are thought to reflect good examples in
the natural selection process in the tropical area. Upon discussing the genetic basis of anemia,
it is prudent to speak about the different hemoglobinopathies and their genes such as sickle
cell anemia. The most commonly mentioned of such genes are Hb S, hemoglobin E, glucose-6-
phosphate dehydrogenase deficiency, pyruvate kinase deficiency hereditary elliptocytosis
(HE), and thalassemia genes where several studies have found an inhibitory effect of thalas‐
semic gene on malaria-related anemia [10].
6. Pathophysiology of malaria-associated anemia
Anemia is one of the primary pathophysiological events contributing to fatal malaria [11].
Severe and refractory anemia causes hypoxia and leads to heart failure in malaria patients [12].
A number of mechanisms contribute to the pathogenesis of malaria-related anemia, such as
erythrocyte destruction and phagocytosis, sequestration of infected RBCs, dyserythropoiesis,
and bone marrow suppression. Erythrocyte lysis could be due to hemolysis of either parasi‐
tized red cells or non-parasitized cells. Red cells of malaria patients suffering from severe
anemia have been found to display abnormal distribution of the different membrane phos‐
pholipids, for example, (phosphatidylserine (PS), phosphatidylcholine, and phosphatidyl
ethanolamine) non-parasitized, along with membrane damage induced by heme released from
the digestion of hemoglobin by the parasite which underwent lipid peroxidation [6].
Expression of specific antibodies directed against the variant parasite antigens (PfEMP-1)
surface of the red cells that results in opsonization of the infected red cells [13]. Interestingly,
lysis of cells is not confined to parasitized RBCs only where it has been found that non-
parasitized erythrocytes inside the parasite culture showed a significant increase in the lipid
peroxide genesis and vulnerability to lysis [14]. Moreover, a direct correlation between
membrane lipid peroxidation and peroxide hemolysis exists, both before and after mono‐
cyte exposure, implying a primary role of membrane peroxidation in red cell lysis. Children
with malaria showed low levels of the antioxidant α-tocopherol in the membrane of red cells,
a finding that might support the hypothesis that local antioxidant consumption may contrib‐
ute to erythrocyte loss. It is also suggested that parasite products forming part of the immu‐
noglobulin-antigen complexes retained on non-parasitized erythrocytes include the P.
falciparum ring surface protein 2 (RSP-2), which results in opsonization of these non-parasi‐
tized RBCs and thus provides a mechanism of removing non-parasitized RBCs [6]. A steady
decline in the hemoglobin level accompanied by an inappropriate reticulocyte response occurs
following an acute malarial infection, where this sort of anemia is explained by sequestra‐
tion of iron in the spleen and other reticuloendothelial system organs together with a short‐
ened red cell survival. It is considered to be very rare in malaria despite the presence of some
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evidences in support of the nature of the normocytic normochromic anemia with evidence of
malaria-related anemia due to hemolysis; however, recent data indicate that these mecha‐
nisms (singly or in combination) do not fully explain the severity of this anemia. Dyserythro‐
poiesis is proposed to play a role in malaria-related anemia, although malaria-related anemia
might partially be attributed to sequestration of parasitized cells, the continuous reduction in
hemoglobin level for several weeks after the acute episode should raise the possibility of
involvement of other factors. Hematologic studies have shown that bone marrow suppres‐
sion and inefficient erythropoiesis have an important share in the severe anemia of malaria
infection [15]. Host mechanisms in control of suppression of erythropoiesis might involve an
exaggerated and steady innate immune response or a pathologic alteration of the T-cell
differentiation response along with the concomitant production of certain proinflammatory
cytokines. We are not to over-look the erythrocytes destructed by the spleen and reticuloen‐
dothelial hyperactivity, where large numbers of both parasitized and non-parasitized red cells
are destructed. Dyserythropoiesis and severe anemia attributed to malaria are closely
associated with excess release of interferon (IFN)-γ and TNF-ᾳ, along with nitrous oxide, which
promote enhanced malarial anemia pathogenesis also resulting in bone marrow suppression
and erythrophagocytosis. Other cytokines like interleukin (IL)-12 and 18 have also been
implicated in dyserythropoiesis. Hemozoin, which is a malarial pigment resulting from
incomplete hemoglobin digestion by the parasite, has also been incriminated in the im‐
paired erythroid development through its direct effects on human monocyte function and/or
erythroid precursors [16]. Other contributing factors to malarial anemia are coinfection with
other organisms such as bacteria, viruses (e.g., human immunodeficiency virus), and helmin‐
thiasis. In summary, the pathogenesis of malaria-related anemia seems to be very complex. It
is indicated that there is a cardinal defect in erythroid maturation with existence of a signifi‐
cant degree of erythrophagocytosis. Nevertheless, more elaboration on the subject of patho‐
physiology of malaria-related anemia is needed. Concerning non-falciparum malaria,
although not common, but it can be seen in the non-falciparum malarial patients, particular‐
ly in cases where hemolysis due to G-6-PD deficiency is encountered and those receiving some
drugs inducing hemolysis. The most important drug to be considered on speaking about
hemolysis due to G-6-PD deficiency is primaquine, which is an effective antimalarial drug
recommended for the dormant hypnozoites of vivax malaria.
7. Mechanisms of anemia in malaria
Increased destruction Inadequate response to anemia
1. Destruction and lysis of
parasitized erythrocytes
2. Destruction and lysis of un parasitized
erythrocytes
3. Drug-induced hemolysis
Dyserythropoiesis due to:
1. Excess IFN-γ
2. Excess TNF-ᾳ
3. Deficient interleukin-12 production
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Increased destruction Inadequate response to anemia
4. Destruction by the spleen and
reticuloendothelial system
4. Effect of hemozoin leading to impaired erythroid development
Table 1. Mechanisms of anemia in malaria.
8. Clinical manifestation of malaria-associated anemia
Malaria-related anemia is a frequent manifestation of P. falciparum malaria; nevertheless, it is
increasingly being reported as a manifestation of P. vivax malaria. The most vulnerable groups
of people are those under five years old and pregnant women. Furthermore, micronutrient
deficiencies caused stunting and also impaired host immunity, thereby increasing the degree
to which malaria is associated with low concentrations of hemoglobin, beside increased
inflammation, and with increased need for iron in young erythroblasts where the anemia might
be severe enough to require blood transfusion. Generally speaking, the spectrum of presen‐
tation is broad and influenced by a number of factors that are host related or parasite related
or a mixture of both such as the age at presentation, whether it is acute or chronic malaria, the
patient’s immune status and if he already lives an endemic area or not and the association with
other conditions that might worsen or protect against the anemia. Pallor is the most common‐
ly encountered presentation of malarial anemia that can be detected by physical examina‐
tion and confirmed by a simple hemoglobin test. Additional symptoms requiring referral and
blood transfusion are an ejection systolic murmur, change in the consciousness level, the
presence of splenomegaly, or malarial parasitemia. In severe malaria-related anemia, it is
proposed that cardiac symptoms could be caused by a cardiomyopathy as an after-effect of
malarial chronic anemia. Moreover, severe malarial anemia might present with severe lactic
acidosis. Severe malarial anemia has been commonly linked to P. falciparum; nevertheless, P.
vivax has been found to cause severe malarial anemia. It is known that parasite density in P.
vivax malaria plays a significant role that influences the fragility of the RBCs, Heinz body
formation, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and
Mean Corpuscular Hemoglobin Concentration (MCHC) levels; there for, the RBCs of the
patients recurrently infected with P. vivax parasite are imposed to structural and functional
dysfunction, finally culminating in anemia. However, the anemia is not an uncommon
presentation in the patients with P. vivax malaria. This is the case that is commonly seen when
antimalarial treatment is used in G-6-PD deficient individuals. As in other types of drug
induced hemolytic anemia, drug-induced P. vivax malaria hemolytic anemia warrants prompt
detection and early management. The type of anemia in P. falciparum malaria is that of
normocytic and normochromic, and absent reticulocytes. Blackwater fever is another type of
hemolytic anemia in malarial patients that tends to present with classical features of hemoly‐
sis such as hemoglobinuria. This fever is a special clinical entity that presents with features of
acute intravascular hemolysis that classically occurs after the reintroduction of quinine in long-
term inhabitants in malaria endemic areas and repeatedly inadequately using it. Those patients
suffering from G-6-PD deficiency are at particular risk of this syndrome, when being subject‐
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ed to oxidant drugs even in the absence of malarial infection. The features of this serious
complication are bilious vomiting, prostration, intravascular hemolysis, hemoglobinuria, and
renal impairment. This is usually a serious and severe complication that should be avoided.
9. Common clinical presentations of malaria-associated anemia
Pallor
Ejection systolic murmur
Change in the consciousness level in association with splenomegaly and parasitemia
Myocardiopathy
Severe lactic acidosis
Blackwater fever
10. Diagnosis of severe malaria-associated anemia
The severe malarial anemia is defined by the World Health Organization (WHO) as:
A hemoglobin less than 5 g/dL or hematocrit less than 15%.
Parasitemia with more than 100,000 parasites/μL of blood.
Normocytic blood film (thus excluding thalassemia as well as iron, B12, and folate deficien‐
cies).
[17, 6].
11. Management of malaria-associated anemia
The fundamentals of management of malaria-related anemia is based on the main principles
of dealing with anemia “improvement of RBC genesis, where decreased RBC production is
the fundamental pathophysiology along with RBC replacement and decrease RBC lysis in
cases that have increase RBC destruction as the culprit pathophysiology” and fundamentals
of management for infection “elimination of the source of infection and control of complica‐
tions from pathogen virulence, host responses and treatment”.
11.1. Role of erythropoietin
Despite the fact that ineffective or inadequate erythropoietin production might contribute to
malaria-associated anemia in some settings; nevertheless, studies from endemic areas such
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as Africa showed that children with malaria have elevated erythropoietin production than
expected. Therefore, a plausible explanation is that it is rather the response to erythropoietin
which contributes to the pathology rather than synthesis, as seen in the anemia of chronic
diseases. And as such, administering erythropoietin is not expected to improve malarial
anemia [6]
11.2. Is there any role for blood transfusion?
The blood transfusion for malaria-related anemia is an old practice that has been practiced
for a long time, the benefits of which have not been validated. Nevertheless, the use of blood
transfusion in management of malaria-related anemia carries a high risk for blood-borne in‐
fections, particularly in poor resource settings where screening in the blood bank process is
lacking or ineffective.
11.3. Is there any role for iron supplementation?
A group of researchers reported that iron supplementation with antimalarial treatment sig‐
nificantly reduced malaria. Moreover, they refuted the assumption that supplementation
during an acute attack of malaria increases the risk for parasitological failure or deaths [18].
11.4. Eliminating source of Infection
Theoretically, the fastest way of getting rid of the source of malarial infection and its prod‐
ucts is the blood exchange, where it was thought to decrease the degree of parasitemia,
when used as adjunct therapy to quinine; however, since there was no supporting evidence,
the CDC is now advising against it [19, 20]. On the other hand, antimalarial drug therapy is
considered to be the slower method for getting rid of the source of infection, and is definite‐
ly needed to manage malaria-related anemia although some of these drugs are to be used
cautiously fearing drug-induced hemolytic anemia.
11.5. Treating coinfecting organisms
Studies addressing the effect of coinfection on malarial anemia showed variable results with
complex outcomes on anemia [21]. Similar outcomes were seen with studies dealing with
the issue of treating coinfection or not [22].
11.6. Control of complications
It is of paramount importance to bear in mind the early recognition of malarial anemia as
one of the serious complications of malaria, and thus it is recommended to include hemoglo‐
bin measurement as part of the management plan of malaria patients at the primary-care
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level, especially in determining whether a patient should be referred to an appropriate treat‐
ment center or not.
11.7. Prevention
The following measures are to be taken so as to prevent and control complications of malar‐
ia-related anemia:
1. Follow-up for the patients to decide on the response to treatment.
2. Control of complications of malaria-related anemia.
3. Close monitoring for the possible complications of malaria related anemia especially for
cardiac and respiratory complications.
4. Monitoring for selected treatment methods such as adverse drug reactions in antimalar‐
ial therapy.
5. Intermittent prophylactic treatment for pregnant women as per the WHO recommenda‐
tions [23].
12. Anemia in schistosomiasis
Schistosomiasis is considered to fall just second to malaria upon discussing the prevalence of
parasitic infestations in the world, being prevalent in more than 70 countries worldwide, with
an infection rate affecting one in each 30 individuals. It is most prevalent in tropical and
subtropical areas of South America, Africa, and Asia. World Health Organization (WHO)
estimates the disease burden to be more than 240 million people infected worldwide, with
400−600 millions of people at risk [24, 25]. Schistosomiasis tends to involve a number of organs
leading to dysfunction of these particular organs, such as renal and bladder dysfunction
(Schistosoma haematobium) or liver and intestinal disease caused by Schistosoma (mansoni,
japonicum, mekongi, and intercalatum) in endemic areas, and it is also a contributory cause of
anemia and stunting of growth. Schistosomiasis is acquired when cercaria breaks through the
skin while swimming or bathing in fresh water when the human host comes into contact with
the infectious, free-living, cercarial larvae that are released by the parasite’s intermediate
hosts [25]. Therefore, patterns of water supply, sanitation, and human water use are critical
factors in defining the risk of infection [25, 26]. Moreover, the geographic distribution of the
different Schistosoma species depends solely on the distribution of the particular snail species
that serve as intermediate hosts. On the other hand, the distribution of snails depends on
climate, water quality, and other ecologic factors [27, 28]. Thanks to animal models of
schistosome infection, where they have allowed intensive study of the immunology and
molecular biology of schistosomiasis. Analysis of host responses to these complex multicellu‐
lar parasites has granted considerable awareness about the regulation of cell-mediated and
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humoral immunity [29], as well as the resistance pathways available for elimination of
macroparasites [30]. Molecular studies of the parasite have granted information on new
manners of genetic expression, not only but even the whole genome of the parasite has been
sequenced [31, 32], as well as leads for the development of vaccines and new pharmaceuti‐
cals for control of this prevalent chronic infection [25].
12.1. Schistosomiasis-related anemia: molecular and genetic basis
The most common presentation of chronic infestation with S. mansoni is with the relatively
asymptomatic intestinal form of the disease, while a minority develops hepatosplenomegaly
characterized by severe hepatic disease complicated by portal hypertension. Such distinct
heterogeneity of disease severity is seen among both, humans and experimental mouse model.
Severe disease is featured by profound hepatic egg-evoked granulomatous inflammation in a
proinflammatory cytokine setting, whereas mild disease conforms with reduced liver
inflammation in a Th2 distorted cytokine setting. This distinct variation reflects that genetic
differences play a pivotal role in disease development. Smith et al. demonstrated in their study,
that severe hepatic pathology in F2 mice 7 wk after infection was significantly associated with
a surge in the synthesis of the proinflammatory cytokines IL-17, IFN-γ, and TNF-α by
schistosome egg antigen-evoked mesenteric lymph node cells. A quantitative analysis of trait
loci revealed a number of genetic intervals governing immunopathology along with IL-17 and
IFN-γ production. Egg granuloma size was found to have a significant linkage to the domi‐
nantly inherited loci; D4Mit203 and D17Mit82. Moreover, these genetic loci were found to have
a decisive effect on the development of immunopathology in murine as evidenced by the
significantly reduced hepatic granulomatous inflammation and IL-17 synthesis in interval-
specific congenic mice [33]. It is likely due to these genetic differences that a minority of infected
persons tends to show the severe form of schistosomiasis with hepatosplenic involvement and
hypersplenism.
12.2. Epidemiology of schistosomiasis-associated anemia
In addition to hookworm anemia, anemia in schistosomiasis poses an important public health
problem, particularly for those tropical countries in Africa where schistosomiasis is endemic
and a strong correlation is found between it and anemia.
12.3. Pathophysiology and manifestations of schistosomiasis-associated anemia
Schistosomiasis or bilharziasis is a group of helminthic infestations that are brought about by
blood flatworms of the Schistosoma genus. The pathology of schistosomiasis is typically
evoked by ova trapped in the tissues, where the activation of CD4 T cell-mediated immunity
results in granulomatous inflammation. Three important forms of schistosomiasis have been
described: intestinal, urinary, and hepatic. The former two forms of schistosomiasis are the
two common forms relating to anemia. It has been noted that there are several negative effects
of the mentioned two forms of schistosomiasis on the coming nutritional parameters in
humans [25]:
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1. Urinary and fecal blood and iron loss
2. Anemia and hemoglobin levels
3. Proteinuria
4. Child growth and adult protein-energy status
5. Physical fitness and physical activity
It is well known that schistosomiasis can cause iron deficiency anemia by direct blood loss in
case of urinary and gastrointestinal schistosomiasis through urine and stools [34]. Interest‐
ingly, the hemoglobin level and the hematocrit were found to be inversely related to egg count,
in contrary to the prevalence of anemia which tends to increase with increasing egg count [35].
There for it is concluded that this negative association between the degree of infection by S.
haematobium and iron status showed a deleterious consequence of urinary schistosomiasis on
nutrition and hematopoietic status, a thing that should be put in consideration when design‐
ing nutrition intervention programs [35]. Other explanations for the anemia associated with
schistosomiasis are the anemia of inflammation and the presence of coinfection with other
parasites such as hook worm [36, 37].
12.4. Schistosomiasis-related anemia: diagnosis and management
The diagnosis of anemia in schistosomiasis needs evidence of coexistence of both anemia
validated by the measurement of hemoglobin and blood fluke infestation by stool or urinary
examination for detection of blood fluke ova. Nevertheless, great care should be taken be‐
cause not all cases with both anemia and blood fluke infestation can be attributed to blood
fluke infestation as anemia can be a common copresentation with helminthic infestation in
tropical countries. Other etiologies for iron deficiency anemia, particularly hookworm infes‐
tation, should be evaluated. Undoubtedly, the coinfestation between hookworm and blood
fluke is reported to coexist in the tropics. Compared to hookworm anemia, treatment of ane‐
mia in schistosomiasis is usually started with an antihelminthic drug. It has been found that
a blanket coverage of a single-dose anthelminthic treatment covering the at-risk population
like school children in the endemic areas achieved hematological benefits among most of the
children with S. haematobium infestation [38]. Such a recommendation is yet waiting estab‐
lishment in the case of pregnant women [39]. The drug of choice for treatment of schistoso‐
miasis infection is praziquantel (40 mg/kg), similar to other fluke infestations. Moreover, the
nutritional supplementation therapy should be similar to hookworm anemia. Nevertheless,
as praziquantel does not reduce the hookworm intensity of infection, which is another major
cause of anemia in the endemic area, alterations in the prevalence of anemia among the pop‐
ulation should be due only to the elimination of Schistosoma species infestation. Accordingly,
in the area with high prevalence of mixed infection of hookworms and blood flukes, com‐
bined antihelminthic drugs for both infestations are advised. It has been found by Friis et al.
that the combination of multi-micronutrient fortification and anthelminthic treatment inde‐
pendently raised the hemoglobin. The treatment effect was thought to be due to decrement
in S. mansoni and hookworm load of infection [40]. However, meta-analysis on this issue did
not support their findings, but rather suggested further research on the subject [41]. It has
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been noted that in areas with schistosomiasis and hookworm infestations, combination
treatment with praziquantel and albendazole, plus iron supplementation, is likely to pro‐
mote good population health and improve hemoglobin levels.
12.5. Schistosomiasis-related anemia: prevention
It is advisable to implement community-level treatment and control of schistosomiasis in
endemic areas where protein-energy malnutrition and anemia frequently coexist where such
strategies will likely improve child growth, appetite, physical fitness, and activity levels and
decrease anemia and symptoms of the infestation [42]. Therefore, screening and early
management of identified cases are the best means to prevent schistosomiasis-associated
anemia. The development of vaccines will give the solution to this dilemma [43].
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